ArticleAnnals of medicine and surgery (2012)2025
Rivaroxaban versus dalteparin for the treatment of cancer-associated venous thromboembolism: a systematic review and meta-analysis.
Bibek Shrestha et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.